APA

Ooki A., Morita S., Iwamoto S., Hara H., Tanioka H., Satake H., Kataoka M., Kotaka M., Kagawa Y., Nakamura M., Shingai T., Ishikawa M., Miyake Y., Suto T., Hashiguchi Y., Yabuno T., Sakamoto J., Tsuji A., Ando M. & Yamaguchi K. (20210423). Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. : Cancer medicine.

Chicago

Ooki Akira, Morita Satoshi, Iwamoto Shigeyoshi, Hara Hiroki, Tanioka Hiroaki, Satake Hironaga, Kataoka Masato, Kotaka Masahito, Kagawa Yoshinori, Nakamura Masato, Shingai Tatsushi, Ishikawa Masashi, Miyake Yasuhiro, Suto Takeshi, Hashiguchi Yojiro, Yabuno Taichi, Sakamoto Junichi, Tsuji Akihito, Ando Masahiko and Yamaguchi Kensei. 20210423. Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. : Cancer medicine.

Harvard

Ooki A., Morita S., Iwamoto S., Hara H., Tanioka H., Satake H., Kataoka M., Kotaka M., Kagawa Y., Nakamura M., Shingai T., Ishikawa M., Miyake Y., Suto T., Hashiguchi Y., Yabuno T., Sakamoto J., Tsuji A., Ando M. and Yamaguchi K. (20210423). Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. : Cancer medicine.

MLA

Ooki Akira, Morita Satoshi, Iwamoto Shigeyoshi, Hara Hiroki, Tanioka Hiroaki, Satake Hironaga, Kataoka Masato, Kotaka Masahito, Kagawa Yoshinori, Nakamura Masato, Shingai Tatsushi, Ishikawa Masashi, Miyake Yasuhiro, Suto Takeshi, Hashiguchi Yojiro, Yabuno Taichi, Sakamoto Junichi, Tsuji Akihito, Ando Masahiko and Yamaguchi Kensei. Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. : Cancer medicine. 20210423.